The Billion Dollar Blind Spot Began in a Doctor’s Office

The story behind The Billion Dollar Blindspot and the structural forces reshaping healthcare innovation and capital allocation.

Special note: My book The Billion Dollar Blindspot is available for pre-order on Amazon and goes live on May 26th. Will you help me make it to #1 on Amazon’s bestseller list?

---

A few years ago, I heard the words from a doctor that sent me on a journey.

It happened at a doctor’s appointment and I remember walking out of that appointment with a realization I could not shake. At the time, what unsettled me was not the diagnosis itself. It was the realization that many of the treatment options for conditions affecting millions of women still felt strangely behind. Almost primitive compared to the sophistication we now expect from modern medicine.

We live in a world of genomic sequencing, AI-driven diagnostics, robotic surgery, and billion-dollar biotech platforms. Entire industries are being rebuilt around precision technology.

And yet in many areas of women’s health, the innovation curve seemed to have flattened decades earlier.

---

At first, I assumed I simply did not know enough. So I started reading. Then reading became research and research became obsession. The deeper I went, the stranger the disconnect became.

For decades, women had been routinely excluded from clinical trials. Drug dosing frameworks were often calibrated around male biology. Diagnostic systems were built around how disease presented in men. The consequences shaped everything from cardiovascular outcomes to autoimmune disease recognition to how pain itself was studied and treated.

And then a different question emerged:

Why hadn’t capital fixed this? Because capital usually finds inefficiency. It identifies unmet need and it prices opportunity. So why had one of healthcare’s largest markets remained systematically under-researched, underfunded, and under-modeled for so long?

That was the moment I realized this was not only a healthcare story. It was a capital markets story. A pattern-recognition failure hiding inside institutional systems.

I had spent more than two decades inside private wealth and institutional finance. I had watched how investors build conviction, how frameworks shape allocation decisions, and how entire categories become visible or invisible depending on the assumptions underneath them.

And I began realizing something I could no longer unsee: When you exclude half the population from foundational research, you do not just create medical blind spots. You create investment blind spots. You create entire categories that sophisticated investors struggle to evaluate because the mental models they inherited were never designed to see them properly.

That became the foundation for my book The Billion Dollar Blindspot.

---

---

This book was written late at night after work. In airport lounges between meetings. Across highlighted studies spread across my desk. Inside conversations with founders, scientists, physicians, investors, and women trying to navigate systems that often did not seem designed around their realities.

One of the most unexpected parts of this process has been realizing how many people around the world were quietly asking similar questions; Investors sensing opportunity but not quite sure how to evaluate it. Founders building important companies while repeatedly hearing the market was “too niche.” Healthcare professionals frustrated by systems designed to react instead of prevent. Women trying to understand why their symptoms had been dismissed for years.

Those conversations started connecting across countries, industries, and disciplines. Which is why I knew the launch for this book could not simply be local.

---

In nine days, on May 26th, I’ll be hosting a global virtual launch conversation joined by three founders featured in the book, bringing together readers, investors, operators, and healthcare professionals from around the world to explore what becomes possible when one of healthcare’s largest overlooked markets finally begins attracting the attention, innovation, and capital it deserves.

The event is free, virtual, and global because the community shaping this conversation already spans the world.

---

And because this community helped shape the book itself, I wanted to make the pre-ordering a participatory experience. So I created a set of pre-order bonuses reserved specifically for early supporters of the book and this growing community.

Bonuses include an extra chapter featuring the stories of three amazing founders building infrastructure in women’s health, priority invitations to future conversations and events, and a live investor Q&A session for readers who want to go deeper into the thesis and investment landscape.

---

If you’ve been following this journey for a while, I would genuinely love for you to be part of launch week.

The e-book is currently available for pre-order for $9.99. And while people often think bestseller lists are about vanity, the reality is more practical than that. Pre-orders are how Amazon decides which books to surface, recommend, and distribute more broadly. In other words: launch week momentum matters….a lot.

Sometimes the largest opportunities remain hidden not because the data is missing…but because the people interpreting the data were trained to miss them. That is what this book is about. And in nine days, it will finally be in your hands.

---

Three years ago, I started writing what I thought was a report. It became a book. Today, The Billion Dollar Blindspot is available for pre-order.

---

Disclaimer & Disclosure

This content is for informational and educational purposes only. It does not constitute financial, investment, legal, or medical advice, or an offer to buy or sell any securities. Opinions expressed are those of the author and may not reflect the views of affiliated organisations. Readers should seek professional advice tailored to their individual circumstances before making investment decisions. Investing involves risk, including potential loss of principal. Past performance does not guarantee future results.